When.com Web Search

  1. Ads

    related to: cost of eylea vs avastin for macular degeneration dystrophy pain
    • Payment Calculator

      Detailed financing estimates.

      Calculate your payment & prequalify

    • Apply Online Now

      See if you prequalify in minutes.

      Accepted at over 260,000 locations!

Search results

  1. Results From The WOW.Com Content Network
  2. US FDA approves higher dose of Regeneron's eye disease drug Eylea

    www.aol.com/news/us-fda-approves-higher-dose...

    The drug, Eylea HD, is priced at $2,625 per single-use vial in the U.S. and is used to treat patients with wet age-related macular degeneration (AMD), diabetic macular edema (DME) and diabetic ...

  3. Anti-VEGF - Wikipedia

    en.wikipedia.org/wiki/Anti-VEGF

    By May 2012, anti-VEGF treatment with Avastin has been accepted by Medicare, is quite reasonably priced, and effective. Lucentis has a similar but smaller molecular structure to Avastin, and is FDA-approved (2006) for treating MacD, yet remains more costly, as is the more recent (approved in 2011) aflibercept (Eylea). Tests on these treatments ...

  4. FDA Approves Biosimilars for Macular Degeneration Treatment - AOL

    www.aol.com/fda-approves-biosimilars-macular...

    The Food and Drug Administration approved two interchangeable biosimilars to Eylea (aflibercept), a brand name drug used to treat age-related macular degeneration, diabetic retinopathy and other ...

  5. Aflibercept - Wikipedia

    en.wikipedia.org/wiki/Aflibercept

    Aflibercept, sold under the brand names Eylea and Zaltrap among others, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. [16] [17] It was developed by Regeneron Pharmaceuticals.

  6. US accuses Regeneron of fraudulent price reporting for eye drug

    www.aol.com/news/us-justice-department-files...

    The drug, which the Tarrytown, New York-based company began marketing in 2011, is approved by the U.S. Food and Drug Administration for treating conditions including wet age-related macular ...

  7. Intravitreal administration - Wikipedia

    en.wikipedia.org/wiki/Intravitreal_administration

    Severe inflammation can cause permanent damage to the eye. The risk of inflammation varies based on the specific drug being administered. One clinical trial of ranibizumab for age-related macular degeneration administered intravitreally reported intraocular inflammation rates between 1.4% and 2.9%.